OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 2,910 UTHR derivative securities | OQRO

Home
Insider trades
United Therapeutics
Director exercised or converted 2,910 UTHR derivative securities

Insider trades

Insider trade

Director exercised or converted 2,910 UTHR derivative securities

Traded Apr 24, 2026 · Filed Apr 25, 2026

UTHUnited TherapeuticsUTHR

2,910
Shares · @ $101.80

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 24, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 25, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001231427-26-000002

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Apr 25, 2026, 12:31 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

Christopher Patusky

Relationship

Director

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Apr 24, 2026

Transaction code

Shares / units

2,910

Price per share

$101.80

Acquired / disposed

Acquired (A)

Shares owned after

4,400

Ownership form

Direct

Amendment

Footnotes from the filing

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 18, 2025.

Around the same time

James EdgemondCFO AND TREASURER

Filed 5mo ago

10KShares · @ $117.76

Traded May 21 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

James Edgemond (CFO AND TREASURER) sold ~$22K of United Therapeutics

Scheduled in advanceFiled 5mo ago

James Edgemond (CFO AND TREASURER) sold ~$179K of United Therapeutics

Scheduled in advanceFiled 5mo ago